Casasnovas, Olivier

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 453

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Cottereau, A.-S., Hapdey, S., Chartier, L., Modzelewski, R., Casasnovas, O., Itti, E., Tilly, H., Vera, P., Meignan, M. A., & Becker, S. (2017) · Journal of Nuclear Medicine

Medical Imaging Techniques and ApplicationsLymphoma Diagnosis and Treatment

Cited by 64

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 41